Gastroenterology
Volume 133, Issue 5 , Pages 1452-1457, November 2007

Clearance of Hepatitis B e Antigen in Patients With Chronic Hepatitis B and Genotypes A, B, C, D, and F

  • Stephen E. Livingston

      Affiliations

    • Liver Disease & Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
    • Corresponding Author InformationAddress requests for reprints to: Stephen E. Livingston, MD, Alaska Native Tribal Health Consortium, Liver Disease & Hepatitis Program, 4315 Diplomacy Drive, ANC-HEP, Anchorage, Alaska 99508. fax: (907) 729-1570.
  • ,
  • Josephine P. Simonetti

      Affiliations

    • Liver Disease & Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
  • ,
  • Lisa R. Bulkow

      Affiliations

    • Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska
  • ,
  • Chriss E. Homan

      Affiliations

    • Liver Disease & Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
  • ,
  • Mary M. Snowball

      Affiliations

    • Liver Disease & Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
  • ,
  • Henry H. Cagle

      Affiliations

    • Liver Disease & Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
  • ,
  • Susan E. Negus

      Affiliations

    • Liver Disease & Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
  • ,
  • Brian J. McMahon

      Affiliations

    • Liver Disease & Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
    • Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska

Received 18 May 2007; accepted 26 July 2007. published online 07 August 2007.

Background & Aims: Persistence of hepatitis B e antigen (HBeAg) in chronic hepatitis B has been associated with increased risk for development of cirrhosis and hepatocellular carcinoma. Five hepatitis B virus genotypes were identified in Alaska Native persons; we analyzed clearance of HBeAg by age and genotype. Methods: In this prospective cohort study, 1158 Alaska Native persons throughout Alaska were tested serially for HBeAg for a median of 20.5 years and were genotyped. Initial and final HBeAg-positive specimens, time to clearance, age at clearance, and subsequent HBeAg results were analyzed for persons initially HBeAg-positive. Subsequent HBeAg results were analyzed for persons initially negative. Results: Genotypes A, B, C, D, and F were identified. Genotype C persons initially HBeAg-positive were more likely than those with other genotypes to be positive on initial and final specimens (P < .001 for each) and time to HBeAg clearance was longer (P < .001). Age at which 50% of persons cleared HBeAg was <20 years for those infected with genotypes A, B, D, and F and 47.8 years in genotype C (P < .001). After losing HBeAg, those with genotypes C and F were more likely to revert to the HBeAg-positive state (P < .001). Conclusions: Genotype may have a strong effect on mode of transmission and outcome. Genotype C may have been responsible for most perinatal transmission, given that seroconversion from HBeAg occurs decades later than in other genotypes.

Abbreviations used in this paper: HBeAg, hepatitis B e antigen, HBsAg, hepatitis B surface antigen, HBV, hepatitis B virus, HCC, hepatocellular carcinoma

 

 Supported by Native American Research Centers for Health (NARCH) grant 1 U26 94 00005-01 from the US Indian Health Services.

PII: S0016-5085(07)01456-4

doi:10.1053/j.gastro.2007.08.010

Refers to article:

  • Hepatitis B: Explosion of New Knowledge

    Emmet B. Keeffe
    Gastroenterology November 2007 (Vol. 133, Issue 5, Pages 1718-1721)

Gastroenterology
Volume 133, Issue 5 , Pages 1452-1457, November 2007